The Ellison Medical Institute (EMI) has entered into an exclusive license with UniQuest, the commercialization company of The ...
The FDA Just Approved a New Drug for an Aggressive Form of Prostate Cancer — and It Targets the Disease in a Way No Approved ...
The metastatic prostate cancer market is undergoing a major transition from conventional ADT toward combination-based, biomarker-driven, and precision-targeted treatment approaches. While AR pathway ...
EDITOR’S NOTE: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine. President Joe Biden’s ...
When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...
The FDA has approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for men with phosphatase and tensin homolog (PTEN)-deficient metastatic androgen pathway ...
PRESS RELEASEAB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER FORMALLY GRANTED IN THE UNITED ...
Many things are evaluated when doctors are putting a treatment plan together for prostate cancer patients. A new study says one more factor should be considered—chronological age. The study, published ...
For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...
A multimodal AI model identified a subset of men with very high-risk localized prostate cancer who derived substantial ...
*Foster Sylvers, the former child star whose youthful voice and magnetic stage presence helped propel The Sylvers to national ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results